Cargando…

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

Detalles Bibliográficos
Autores principales:	Wong, Michael K, Daniels, Gregory A, Kaufman, Howard L, McDermott, David F, Morse, Michael A, Aung, Sandra, Lowder, James N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991220/ http://dx.doi.org/10.1186/2051-1426-1-S1-P67

Ejemplares similares

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
por: Kaufman, Howard L., et al.
Publicado: (2014)

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
por: Wong, Michael K, et al.
Publicado: (2014)

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry
por: Curti, Brendan, et al.
Publicado: (2017)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM(SM)
por: Clark, Joseph I., et al.
Publicado: (2016)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
por: Chandar, Ashwin, et al.
Publicado: (2015)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016)

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020)

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
por: Dutcher, Janice P, et al.
Publicado: (2014)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

The Gospel of Hahnemann: How Are We Proclaiming It?
por: Kennedy, A. L.
Publicado: (1899)

Higher Doses for Heavy Hives
por: Godse, Kiran, et al.
Publicado: (2013)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

Higher dose statins after stroke
Publicado: (2021)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

EBASTINE IN CHRONIC SPONTANEOUS URTICARIA IN HIGHER DOSES
por: Godse, Kiran V
Publicado: (2011)

Fexofenadine in higher doses in chronic spontaneous urticaria
por: Godse, Kiran V., et al.
Publicado: (2010)

Remdesivir for COVID-19: Why Not Dose Higher?
por: Yan, Victoria C., et al.
Publicado: (2021)

Scientific rationale for a higher dose of nusinersen
por: Finkel, Richard S., et al.
Publicado: (2022)

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
por: Zloza, Andrew, et al.
Publicado: (2013)

CX-072 (pacmilimab), a Probody(®) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
por: Naing, Aung, et al.
Publicado: (2021)

Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes?
por: Kaufman-Janette, Joely, et al.
Publicado: (2021)

Higher doses of naloxone are needed in the synthetic opiod era
por: Moss, Ronald B., et al.
Publicado: (2019)

Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia?
por: Perner, Anders, et al.
Publicado: (2023)

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?
por: Dreher, Constantin, et al.
Publicado: (2017)

Giardiasis Pattern among Different Age Categories: Childhood Assemblage B Proclaim Endemicity
por: AHMED, Doaa A., et al.
Publicado: (2019)

The Prevalence of Undiagnosed Age-Related Sight-Threatening Diseases in Self-Proclaimed Healthy Individuals
por: Lemmens, Sophie, et al.
Publicado: (2020)

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
por: Chu, Melinda, et al.
Publicado: (2015)

Recent trial on Vitamin D: Higher dose increases fall?
por: Hajra, Adrija, et al.
Publicado: (2016)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria
por: Watson, James A., et al.
Publicado: (2022)

Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?
por: Lewis, T.S., et al.
Publicado: (2020)

Corticosteroid-Induced Mania After Previous Tolerance of Higher Doses
por: Jasani, Reena, et al.
Publicado: (2021)

Ionizing Radiation, Higher Plants, and Radioprotection: From Acute High Doses to Chronic Low Doses
por: Caplin, Nicol, et al.
Publicado: (2018)

Dose-response relationship between higher serum calcium level and higher prevalence of hyperuricemia: A cross-sectional study
por: Liu, Zhichen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jur9uonvvs0rc8rkf54b4sb34f